Press Release | Sat Jun 22, 2013 11:00am EDT

Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin after 14 Days as Add-on to Insulin in Adult Patients with Type 1 Diabetes Presented at the 2013 American Diabetes Association Scientific Sessions®

* Reuters is not responsible for the content in this press release.